Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arrowhead Pharmaceuticals reports strong Q1 earnings and outlines growth strategy

Arrowhead Pharmaceuticals showcased solid financial performance, promising clinical outcomes, and a strategic growth plan during the Q1 2023 earnings call.
While facing challenges in financial losses and program complexities, the company's strengths in innovation, partnerships, and pipeline development position them for future success.
Opportunities lie in upcoming data releases, therapeutic advancements, and strategic collaborations, offering avenues for market expansion and medical breakthroughs.
Overall, Arrowhead Pharmaceuticals demonstrates resilience, innovation, and a clear vision for growth in the competitive biopharmaceutical landscape.

Arrowhead Pharmaceuticals reports robust Q2 earnings and expands pipeline

Arrowhead Pharmaceuticals delivered strong financial results and showcased progress in its drug pipeline, particularly in the pulmonary and CNS spaces.
While facing challenges in translating preclinical success to clinical outcomes and navigating competitive landscapes, the company's strategic partnerships and efficient cost management are key strengths.
Opportunities lie in expanding into new therapeutic areas, leveraging external interest for internal development, and benefiting from regulatory insights in the CNS field.
Overall, Arrowhead Pharmaceuticals remains well-positioned for future growth and innovation in the biopharmaceutical sector.

Arrowhead Pharmaceuticals advances pipeline with strong financial backing

Arrowhead Pharmaceuticals made progress in de-risking its pulmonary franchise and advancing key cardiometabolic candidates.
The company's strong financial position and focus on partnerships support its goal of expanding the pipeline to 20 products by 2025.
Challenges include high operating expenses, the need for specific financing for trials, and managing cash burn effectively.
Exploration of CNS targets and upcoming Phase 2 data presentations offer growth opportunities for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals advances key products towards commercialization amid financial challenges

Arrowhead Pharmaceuticals made significant progress on key products and is advancing towards commercialization and de-risking their pipeline.
Despite facing a net loss, the company remains focused on expanding their product portfolio and exploring new treatment options.
Strategic partnerships and ongoing research efforts position Arrowhead well for future growth and potential commercial success.
Managing financial challenges and optimizing trial strategies will be crucial for Arrowhead's continued success in the biopharmaceutical industry.

Arrowhead Pharmaceuticals advances RNAi pipeline with cardiometabolic focus

Arrowhead Pharmaceuticals focuses on advancing RNAi therapeutics with a cardiometabolic emphasis.
Financials show a net loss with plans to strengthen the balance sheet and decrease operating expenses.
Exploring debt financing, partnerships, and new innovations for pipeline expansion and commercial growth.
Challenges include data delays, uncertain timelines, and the need for additional biomarker data.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will participate in upcoming October 2021 conferences

Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals earned a $10 million milestone from Janssen when RNAi candidate ARO-JNJ1 entered a Phase 1 clinical trial

Arrowhead Earns $10 Million Phase 1 Milestone Payment

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

Arrowhead Pharmaceuticals is a leading innovator in promising drugs to treat crippling diseases. This piece focuses on its two most advanced liver disease drugs in trial, which also form the practical core of two key partnerships.

The Partnership Effect: Arrowhead Forges Its Future

Carnival

Duke Energy

Petco Health and Wellness

American Water Works

Okta

Zscaler

With the trading day more than halfway over, the broad markets were somewhat mixed.

Friday Afternoon Analyst Upgrades and Downgrades: Carnival, Duke Energy, Petco Health and More

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2021 Results - Earnings Call Transcript

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08% year over year to ($0.29), which missed the estimate of ($0.20).

Recap: Arrowhead Pharmaceuticals Q3 Earnings

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals reports fiscal 2021 third quarter results and holds a webcast and conference call

Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead receives breakthrough therapy designation for ARO-AAT and announces full enrollment for SEQUOIA Phase 2 clinical trial

Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

This biotech underdog offers more than meets the eye.

Arrowhead Pharmaceuticals: Buy the Dip?

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 third quarter results

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results

The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after the company decided to pause its early stage clinical trials for AROENaC1001, the company's investigational treatment.

Will Arrowhead Stock Rebound After A Large 30% Decline Last Week?

Arrowhead's stock dropped 25% on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. While safety issue noted with ARO-ENaC for Cystic Fibrosis, there's another clinical candidate targeting a large multi-billion dollar market like JNJ-3989 for the treatment of patients with Hepatitis B.

Arrowhead Pharmaceuticals Dives On Safety Issues For ARO-ENaC, But Remains On Track In Other Indications

The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.

Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell carcinoma (ccRCC).  ARO-HIF2 is the first tumor-targeted investigational medicine to utilizing Arrowhead's Targeted RNAi Molecule (TRiM) platform.

Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim results on RNAi investigational medicine ARO-HIF2 in patients with renal cell carcinoma

Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

A paused clinical trial with an important asset wasn't what investors wanted to hear today.

Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the company's investigational RNA interference (RNAi) therapeutic.

Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals dosed the first patient in a Phase 2b clinical study of ARO-ANG3 an RNAi therapeutic to treat mixed dyslipidemia

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Takeda presented positive clinical trial data on rare orphan disease RNAi drug ARO-AAT at EASL The International Liver Congress

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals presented preclinical data on the development of ARO-DUX4 at 28th Annual FSHD Society International Research Congress

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead presents data at EASL showing ARO-HSD reduces HSD17B13 mRNA and protein in the liver leading to reductions in ALT

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress

Horizon Pharma

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pay $40 million upfront for global rights to Arrowhead Pharmaceuticals' ARO-XDH, an investigational RNAi therapy.

Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate

PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) today announced a global collaboration and license agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout. Gout is a serious and painful form of arthritis that is caused by excess uric acid in the blood. In the Unite

News for Arrowhead Pharmaceuticals Stock (ARWR)